Consequences of activating the calcium-permeable ion channel TRPV1 in breast cancer cells with regulated TRPV1 expression

Cell Calcium

Volumn 56, Issue 2, 2014, Pages 59-67

  Wu, Tina T L ^a   Peters, Amelia A ^a   Tan, Ping T ^a   Roberts Thomson, Sarah J ^a   Monteith, Gregory R ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Breast cancer; Calcium, Necrosis; TRPV1

Indexed keywords

CALCIUM ION; CAPSAICIN; CELL MARKER; PROTEIN C FOS; PROTEIN RIP3; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; CALCIUM; DOXORUBICIN; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RIPK3 PROTEIN, HUMAN; TRPV1 PROTEIN, HUMAN; VANILLOID RECEPTOR;

ARTICLE; BREAST CANCER CELL LINE; CANCER CELL DESTRUCTION; CELL DEATH; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; MCF 7 CELL LINE; PHARMACOLOGICAL STIMULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; BREAST TUMOR; CELL SURVIVAL; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; METABOLISM; PATHOLOGY; TOXICITY;

BREAST NEOPLASMS; CALCIUM; CAPSAICIN; CELL PROLIFERATION; CELL SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MCF-7 CELLS; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; TRPV CATION CHANNELS; UP-REGULATION;

EID: 84904539783     PISSN: 01434160     EISSN: 15321991     Source Type: Journal    
DOI: 10.1016/j.ceca.2014.04.006     Document Type: Article

References (74)

1. 2+ transport. Nat. Rev. Cancer 2007, 7:519-530.
2. Prevarskaya N., Skryma R., Shuba Y. Calcium in tumour metastasis: new roles for known actors. Nat. Rev. Cancer 2011, 11:609-618.
3. Henshall S.M., Afar D.E., Hiller J., et al. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 2003, 63:4196-4203.
4. Tsavaler L., Shapero M.H., Morkowski S., Laus R. Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res. 2001, 61:3760-3769.
5. 2+-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. Oncogene 2003, 22:7858-7861.
6. Peng J.B., Zhuang L., Berger U.V., et al. CaT1 expression correlates with tumor grade in prostate cancer. Biochem. Biophys. Res. Commun. 2001, 282:729-734.
7. Monet M., Lehen'kyi V., Gackiere F., et al. Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance. Cancer Res. 2010, 70:1225-1235.
8. Yang S.L., Cao Q., Zhou K.C., Feng Y.J., Wang Y.Z. Transient receptor potential channel C3 contributes to the progression of human ovarian cancer. Oncogene 2009, 28:1320-1328.
9. Wan Q., Zheng A., Liu X., Chen Y., Han L. Expression of transient receptor potential channel 6 in cervical cancer. Onco Targets Ther. 2012, 5:171-176.
10. Peters A.A., Simpson P.T., Bassett J.J., et al. Calcium channel TRPV6 as a potential therapeutic target in estrogen receptor-negative breast cancer. Mol. Cancer Ther. 2012, 11:2158-2168.
11. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:8418-8423.
12. Yang S., Zhang J.J., Huang X.Y. Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. Cancer Cell 2009, 15:124-134.
13. Aydar E., Yeo S., Djamgoz M., Palmer C. Abnormal expression, localization and interaction of canonical transient receptor potential ion channels in human breast cancer cell lines and tissues: a potential target for breast cancer diagnosis and therapy. Cancer Cell Int. 2009, 9:23.
14. Kalogris C., Caprodossi S., Amantini C., et al. Expression of transient receptor potential vanilloid-1 (TRPV1) in urothelial cancers of human bladder: relation to clinicopathological and molecular parameters. Histopathology 2010, 57:744-752.
15. Shi Y., Ding X., He Z.H., Zhou K.C., Wang Q., Wang Y.Z. Critical role of TRPC6 channels in G2 phase transition and the development of human oesophageal cancer. Gut 2009, 58:1443-1450.
16. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
17. Zhang L., Barritt G.J. Evidence that TRPM8 is an androgen-dependent Ca2+ channel required for the survival of prostate cancer cells. Cancer Res. 2004, 64:8365-8373.
18. Berridge M.J., Bootman M.D., Lipp P. Calcium - a life and death signal. Nature 1998, 395:645-648.
19. Orrenius S., Zhivotovsky B., Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat. Rev. Mol. Cell Biol. 2003, 4:552-565.
20. 2+ exchanger in excitotoxicity. Cell 2005, 120:275-285.
21. Schwab B.L., Guerini D., Didszun C., et al. Cleavage of plasma membrane calcium pumps by caspases: a link between apoptosis and necrosis. Cell Death Differ. 2002, 9:818-831.
22. Curry M.C., Luk N.A., Kenny P.A., Roberts-Thomson S.J., Monteith G.R. Distinct regulation of cytoplasmic calcium signals and cell death pathways by different plasma membrane calcium ATPase isoforms in MDA-MB-231 breast cancer cells. J. Biol. Chem. 2012, 287:28598-28608.
23. Sherkheli M.A., Vogt-Eisele A.K., Bura D., Beltran M.L.R., Gisselmann G., Hatt H. Characterization of selective TRPM8 ligands and their structure activity response (S.A.R) relationship. J. Pharm. Pharm. Sci. 2010, 13:242-253.
24. Li Q., Wang X., Yang Z., Wang B., Li S. Menthol induces cell death via the TRPM8 channel in the human bladder cancer cell line T24. Oncology 2009, 77:335-341.
25. 2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival. Cancer Gene Ther. 2003, 10:611-625.
26. Reilly C.A., Taylor J.L., Lanza D.L., Carr B.A., Crouch D.J., Yost G.S. Capsaicinoids cause inflammation and epithelial cell death through activation of vanilloid receptors. Toxicol. Sci. 2003, 73:170-181.
27. Yamada T., Ueda T., Shibata Y., et al. TRPV2 activation induces apoptotic cell death in human T24 bladder cancer cells: a potential therapeutic target for bladder cancer. Urology 2010, 76:e1-e7. 509.
28. Capiod T. Cell proliferation, calcium influx and calcium channels. Biochimie 2011, 93:2075-2079.
29. Tominaga M., Caterina M.J., Malmberg A.B., et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998, 21:531-543.
30. Southall M.D., Li T., Gharibova L.S., Pei Y., Nicol G.D., Travers J.B. Activation of epidermal vanilloid receptor-1 induces release of proinflammatory mediators in human keratinocytes. J. Pharmacol. Exp. Ther. 2003, 304:217-222.
31. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389:816-824.
32. Fernandes E.S., Fernandes M.A., Keeble J.E. The functions of TRPA1 and TRPV1: moving away from sensory nerves. Br. J. Pharmacol. 2012, 166:510-521.
33. Grant A., Amadesi S., Bunnett N.W. Protease-activated receptors mechanisms by which proteases sensitize TRPV channels to induce neurogenic inflammation and pain. TRP Ion Channel Function in Sensory Transduction and Cellular Signaling Cascades 2007, CRC Press, Boca Raton, FL, USA. W.B. Liedtke, S. Heller (Eds.).
34. Xia R., Dekermendjian K., Lullau E., Dekker N. TRPV1: a therapy target that attracts the pharmaceutical interests. Adv. Exp. Med. Biol. 2011, 704:637-665.
35. Domotor A., Peidl Z., Vincze A., et al. Immunohistochemical distribution of vanilloid receptor, calcitonin-gene related peptide and substance P in gastrointestinal mucosa of patients with different gastrointestinal disorders. Inflammopharmacology 2005, 13:161-177.
36. Hartel M., di Mola F.F., Selvaggi F., et al. Vanilloids in pancreatic cancer: potential for chemotherapy and pain management. Gut 2006, 55:519-528.
37. Czifra G., Varga A., Nyeste K., et al. Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma. J. Cancer Res. Clin. Oncol. 2009, 135:507-514.
38. Sanchez M.G., Sanchez A.M., Collado B., et al. Expression of the transient receptor potential vanilloid 1 (TRPV1) in LNCaP and PC-3 prostate cancer cells and in human prostate tissue. Eur. J. Pharmacol. 2005, 515:20-27.
39. Malagarie-Cazenave S., Olea-Herrero N., Vara D., Diaz-Laviada I. Capsaicin, a component of red peppers, induces expression of androgen receptor via PI3K and MAPK pathways in prostate LNCaP cells. FEBS Lett. 2009, 583:141-147.
40. Sanchez A.M., Sanchez M.G., Malagarie-Cazenave S., Olea N., Diaz-Laviada I. Induction of apoptosis in prostate tumor PC-3 cells and inhibition of xenograft prostate tumor growth by the vanilloid capsaicin. Apoptosis 2006, 11:89-99.
41. Aung C.S., Ye W., Plowman G., Peters A.A., Monteith G.R., Roberts-Thomson S.J. Plasma membrane calcium ATPase 4 and the remodeling of calcium homeostasis in human colon cancer cells. Carcinogenesis 2009, 30:1962-1969.
42. Suchanek K.M., May F.J., Robinson J.A., et al. Peroxisome proliferator-activated receptor alpha in the human breast cancer cell lines MCF-7 and MDA-MB-231. Mol. Carcinog. 2002, 34:165-171.
43. Plantin-Carrenard E., Bringuier A., Derappe C., et al. A fluorescence microplate assay using yopro-1 to measure apoptosis: application to HL60 cells subjected to oxidative stress. Cell Biol. Toxicol. 2003, 19:121-133.
44. Sgonc R., Gruber J. Apoptosis detection: an overview. Exp. Gerontol. 1998, 33:525-533.
45. Vercelli C., Barbero R., Cuniberti B., Odore R., Re G. Expression and functionality of TRPV1 receptor in human MCF-7 and canine CF.41 cells. Vet. Comp. Oncol. 2013, 9999.
46. Xue L.Y., Chiu S.M., Oleinick N.L. Staurosporine-induced death of MCF-7 human breast cancer cells: a distinction between caspase-3-dependent steps of apoptosis and the critical lethal lesions. Exp. Cell Res. 2003, 283:135-145.
47. Mooney L.M., Al-Sakkaf K.A., Brown B.L., Dobson P.R. Apoptotic mechanisms in T47D and MCF-7 human breast cancer cells. Br. J. Cancer 2002, 87:909-917.
48. Rello S., Stockert J.C., Moreno V., et al. Morphological criteria to distinguish cell death induced by apoptotic and necrotic treatments. Apoptosis 2005, 10:201-208.
49. Pingle S.C., Matta J.A., Ahern G.P. Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb. Exp. Pharmacol. 2007, 155-171.
50. 2+ for cancer cell proliferation and survival. Nat. Rev. Cancer 2008, 8:361-375.
51. Zhang D.W., Shao J., Lin J., et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009, 325:332-336.
52. Welz P.S., Wullaert A., Vlantis K., et al. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature 2011, 477:330-334.
53. 2+ release from endoplasmic reticulum and Golgi. J. Biol. Chem. 2007, 282:3325-3336.
54. Kahl C.R., Means A.R. Regulation of cell cycle progression by calcium/calmodulin-dependent pathways. Endocr. Rev. 2003, 24:719-736.
55. Berridge M.J. The AM and FM of calcium signalling. Nature 1997, 386:759-760.
56. Berridge M.J., Lipp P., Bootman M.D. The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell Biol. 2000, 1:11-21.
57. Landowski C.P., Bolanz K.A., Suzuki Y., Hediger M.A. Chemical inhibitors of the calcium entry channel TRPV6. Pharm. Res. 2011, 28:322-330.
58. Amaravadi R.K., Thompson C.B. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin. Cancer Res. 2007, 13:7271-7279.
59. Kepp O., Tesniere A., Schlemmer F., et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 2009, 14:364-375.
60. Zong W.X., Thompson C.B. Necrotic death as a cell fate. Genes Dev. 2006, 20:1-15.
61. de B.E.C., Medema J.P. Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat. Rev. 2008, 34:737-749.
62. Olive P.L., Vikse C.M., Vanderbyl S. Increase in the fraction of necrotic, not apoptotic, cells in SiHa xenograft tumours shortly after irradiation. Radiother. Oncol. 1999, 50:113-119.
63. Whitacre C.M., Satoh T.H., Xue L., Gordon N.H., Oleinick N.L. Photodynamic therapy of human breast cancer xenografts lacking caspase-3. Cancer Lett. 2002, 179:43-49.
64. Zong W.X., Ditsworth D., Bauer D.E., Wang Z.Q., Thompson C.B. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev. 2004, 18:1272-1282.
65. Olofsson M.H., Ueno T., Pan Y., et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res. 2007, 13:3198-3206.
66. Sun X., Li Y., Li W., et al. Selective induction of necrotic cell death in cancer cells by beta-lapachone through activation of DNA damage response pathway. Cell Cycle 2006, 5:2029-2035.
67. Hess J., Angel P., Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J. Cell Sci. 2004, 117:5965-5973.
68. Shaulian E., Karin M. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 2002, 4:E131-E136.
69. Sheng M., Dougan S.T., McFadden G., Greenberg M.E. Calcium and growth factor pathways of c-fos transcriptional activation require distinct upstream regulatory sequences. Mol. Cell. Biol. 1988, 8:2787-2796.
70. Chang W.C., Nelson C., Parekh A.B. Ca2+ influx through CRAC channels activates cytosolic phospholipase A2, leukotriene C4 secretion, and expression of c-fos through ERK-dependent and -independent pathways in mast cells. FASEB J. 2006, 20:2381-2383.
71. Colotta F., Polentarutti N., Sironi M., Mantovani A. Expression and involvement of c-fos and c-jun protooncogenes in programmed cell death induced by growth factor deprivation in lymphoid cell lines. J. Biol. Chem. 1992, 267:18278-18283.
72. Preston G.A., Srinivasan D., Barrett J.C. Apoptotic response to growth factor deprivation involves cooperative interactions between c-Fos and p300. Cell Death Differ. 2000, 7:215-226.
73. Marti A., Jehn B., Costello E., et al. Protein kinase A and AP-1 (c-Fos/JunD) are induced during apoptosis of mouse mammary epithelial cells. Oncogene 1994, 9:1213-1223.
74. Madeo A., Vinciguerra M., Lappano R., et al. c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells. Oncogene 2010, 29:978-991.